NEW YORK, May 10 – Orchid Biosciences reported revenues of $5.6 million for the first quarter of 2001 Thursday, up from $3.5 million in the comparable quarter last year.

Orchid attributed the revenue increase to sales of its SNPstream SNP scoring and DNA testing services, collaboration and license fees, and revenues from Cellmark Diagnostics, a genetic testing company Orchid acquired in February of 2001.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.